
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Services-Prepackaged Software · market cap $111M
Research and calibrated estimates, not financial advice — verify before acting.
No upcoming catalysts in our calendar.
| Asset | Phase | Indication |
|---|---|---|
| Emixustat | Phase 3 | Stargardt Disease |
| Drug: GB-102 | Phase 2 | Neovascular Age-Related Macular Degeneration |
| SHJ002/Vehicle | Phase 2 | Dry Eye Disease |
| Netarsudil Ophthalmic Solution | Phase 3 | Fuchs Endothelial Dystrophy |
| EV06 Ophthalmic Solution | Phase 2 | Presbyopia |
| Riboflavin | Phase 2 | Keratoconus |
| emixustat hydrochloride | Phase 2 | Proliferative Diabetic Retinopathy |
| rebamipide 2% ophthalmic suspension | Phase 3 | Dry Eye Syndromes |
| OPA-6566 | Phase 2 | Primary Open-angle Glaucoma |
| ACU-4429 | Phase 3 | Geographic Atrophy |
| GB-102 | Phase 2 | Diabetic Macular Edema |
| SHJ002 | Phase 2 | Myopia, Progressive |
| Prednisolone acetate | Phase 2 | Fuchs' Dystrophy |
Daily closes through 2026-06-25. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
See ProApproval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.